Detail akcie Fractyl Health Rg online

Business Summary: Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Fractyl Health Inc revenues decreased from $90K to $0K. Net loss applicable to common stockholders increased from $45.5M to $97.2M. Revenues reflect Biotechnology & Medical Research segment decrease from $14K to $0K. Higher net loss reflects Biotechnology & Medical Research segment loss increase from $23.8M to $73.5M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.95 to -$1.76.